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Aspergillosis refers to a spectrum of disorders that can occur due to colonization with the Aspergillus fungus. Allergic bronchopulmonary aspergillosis (ABPA) is an airway hypersensitivity reaction to the fungus that is almost exclusively seen in patients
with cystic ﬁbrosis or asthma. Here, we present a case of ABPA in a patient with a history of chronic cocaine use and tuberculosis
and no history of asthma or cystic ﬁbrosis. The patient had presented with progressively worsening dyspnea for three months as
well as a 20-pound weight loss. Diagnosis was made with an elevated IgE against Aspergillus and chest CT ﬁndings, which included
bronchiectasis and tree-in-bud nodular opacities. The patient was treated with IV methylprednisolone followed by a 4-day course
of oral prednisone, with signiﬁcant improvement. It is our hope to make healthcare providers aware of the potential presence of
ABPA in chronic cocaine users and patients with tuberculosis, both of which are not traditionally associated with this condition.

1. Introduction
Aspergillosis refers to a spectrum of disorders that can
occur due to colonization with the Aspergillus fungus.
Spores are commonly airborne in the environment but
only classically cause disease in immunocompromised
patients. Aspergillus is unique in the fact that it can result
in either infectious or atopic manifestations. Types of
aspergillosis diseases include allergic Aspergillus sinusitis, aspergilloma, invasive aspergillosis, fungal
asthma, and allergic bronchopulmonary aspergillosis
(ABPA) [1].
ABPA is an airway hypersensitivity reaction to the
fungus that is almost exclusively seen in patients with cystic
ﬁbrosis or asthma [2, 3]. The estimated prevalence of ABPA
among patients with asthma is approximately 1–2% [4].
The prevalence is slightly higher in patients with cystic
ﬁbrosis, estimating about 2–9% [5]. In rare cases, ABPA
can be seen in lung transplant recipients or those with
bronchiectasis, chronic granulomatous disease, or hyperIgE syndrome [6].

The International Society for Human and Animal Mycology (ISHAM) provides a proposed set of diagnostic
criteria for ABPA (Table 1) [7].These criteria are divided into
three groupings: predisposing conditions, obligatory criteria, and other criteria. One of the following predisposing
conditions must be present: asthma or cystic ﬁbrosis. Both of
the following obligatory criteria must be present: positive
Aspergillus skin test or IgE levels against Aspergillus that are
detectable and an elevated serum IgE concentration. At least
2 of the following “other criteria” must be present: precipitating Aspergillus serum antibodies, pulmonary opacities
seen on chest radiograph, or a serum eosinophil count
greater than 500 cells/microliter in patients who have not
been on glucocorticoids.
Despite the requirement of one predisposing condition,
ISHAM notes that a diagnosis of ABPA is still possible in
patients without asthma or cystic ﬁbrosis, albeit very rare
[8]. The objective of this case report is to highlight a rare
case of ABPA in a patient with a history of chronic cocaine
use and tuberculosis and no history of asthma or cystic
ﬁbrosis.
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Table 1: ISHAM criteria for diagnosis of ABPA.

Predisposing conditions
Obligatory criteria

Other criteria

Requirements: 1 of 2; rarely, none are present
Asthma
Cystic ﬁbrosis
Requirements: 2 of 2
Elevated serum IgE concentration
Elevated IgG or IgE against Aspergillus fumigatus
Requirements: 2 of 3
Serum eosinophil count >500 cells/microliter
Radiographic changes consistent with ABPA
Serum antibodies to Aspergillus fumigatus or elevated
serum Aspergillus IgG

2. Case Presentation
This patient is a 57-year-old male with a past medical history
of tuberculosis and a signiﬁcant social history of chronic
cocaine use who presented to the emergency department due
to progressively worsening dyspnea over the last three
months. On physical exam, the patient had diﬀuse wheezing.
He also endorsed a 20-pound weight loss over the last three
months and increased urinary retention. The patient denied
fevers, chills, recent travel, hemoptysis, and cigarette
smoking.
During his hospital stay, the following labs were performed: Acid-fast bacilli smear, Mycobacterium polymerase
chain reaction, Legionella antigen, urine drug screen, immunoglobulin E (IgE) levels, Aspergillus antigen, and neutrophilic cytoplasmic antibody. Acid-fast bacilli testing was
negative, as well as mycobacterium polymerase chain reaction, Legionella antigen, and neutrophilic cytoplasmic
antibody. Urine drug screen was positive for cocaine. Eosinophil
count
was
elevated
at
670 cells/μL
(normal < 610 cells/μL). IgE level was also elevated at
2,378 kU/L (normal < 114 kU/L). Based on ﬁndings of elevated IgE levels, IgE against Aspergillus fumigatus was sought
out and came back positive (0.56 kU/L).
Chest X-ray revealed hyperinﬂation, ﬂattened diaphragm, and pleural thickening (Figure 1). Chest CT
without contrast revealed some bronchial wall thickening
and bronchiectasis in the bilateral lower lobes (Figure 2(a)).
In the right upper lobe, there was also some bronchial wall
thickening, bronchiectasis, and tree-in-bud nodularity
(Figure 2(b)). A 1.0 × 2.2 × 1.8 cm solid nodule was visualized
in the posterior medial right lung (Figure 2(c)). This was
grossly stable in size from a chest CT 3 months prior.
The patient was ﬁrst treated at an outside hospital for
pneumonia with amoxicillin-clavulanate and a 7-day course
of prednisone 10 mg at the ﬁrst onset of his symptoms. He
reported transient improvement with steroids. On presentation, prior to conﬁrmation of ABPA, the patient was
treated with 60 mg intravenous methylprednisolone BID
and inhaled ipratropium bromide with albuterol sulfate.
Once ABPA was conﬁrmed, the patient was transitioned
from methylprednisolone to a 4-day treatment course with
60 mg oral prednisone. The patient noted signiﬁcant improvement prior to discharge.
Given the concern for malignancy due to signiﬁcant
weight loss and urinary retention, the prostate-speciﬁc

Figure 1: Posterior-anterior chest X-ray revealing hyperinﬂation,
ﬂattened diaphragm, and pleural thickening.

antigen (PSA) was measured. This was elevated at 11.2 ng/ml
(normal < 4.0 ng/ml). Urology was consulted, and outpatient
follow-up with urology was recommended for a transrectal
ultrasound- (TRUS-) guided biopsy.

3. Discussion
Aspergillosis refers to a spectrum of disorders that can occur
due to colonization with a type of Aspergillus fungus, most
commonly Aspergillus fumigatus. Spores are commonly
airborne in the environment yet rarely cause disease in
immunocompetent patients. On the other hand, immunocompromised patients are at risk of various presentations of
disease due to inhalation of the fungus. Aspergillus is unique
in the fact that it can result in either infectious or atopic
manifestations. Types of aspergillosis infections include
allergic Aspergillus sinusitis, aspergilloma, invasive aspergillosis, and allergic bronchopulmonary aspergillosis [1].
Allergic Aspergillus sinusitis (AAS) is a hypersensitivity
reaction to Aspergillus that results in sinusitis. The reaction is
similar to that of allergic bronchopulmonary aspergillosis;
however, it occurs in the sinuses. Despite the similar
mechanism of colonization, few cases report simultaneous
presence of both diseases [9]. Patients at risk for developing
AAS include those with a prior sensitization to the Aspergillus antigen who also have a past medical history of asthma
or rhinosinusitis [10].
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(a)

(b)

(c)

Figure 2: Chest CT without contrast revealing (a) bronchial wall thickening and bronchiectasis in the bilateral lower lobes; (b) bronchial
wall thickening, bronchiectasis, and tree-in-bud nodularity; and (c) a 1.0 × 2.2 × 1.8 cm solid nodule in the posterior medial right lung.

An aspergilloma is an intracavitary fungus ball that
typically presents in previously colonized areas of the lung
[11]. For this reason, many patients may have a history of
colonization with Mycobacterium tuberculosis. [12]. Chest
X-ray shows a cavitary lesion with a thickened wall. In most
instances, this is an incidental ﬁnding, and patients remain
asymptomatic. Rarely, patients can present with hemoptysis
secondary to blood vessel invasion. Aspergillus sensitization
has also been commonly reported in the setting of pulmonary tuberculosis cavitary disease [12]. Dhooria et al.
reported that 16% of patients with a history of pulmonary
tuberculosis had Aspergillus sensitization. Nevertheless, a
diagnosis of tuberculosis is not a “predisposing condition” in
the ISHAM criteria [12].
Invasive aspergillosis refers to systemic dissemination of
the fungus. Normally, alveolar macrophages and epithelial
cells work together to rid the lungs of infection before
dissemination can occur [13]. In cases where this is ineﬃcient, the fungi are able to latch onto blood vessels, invade
the endothelium, and spread throughout the body. Risk
factors for invasive aspergillosis include severe neutropenia,

glucocorticoids given in high doses, AIDS, and immunosuppression [14]. Once the fungus becomes systemic, it can
aﬀect almost every organ, including the liver, kidneys, eyes,
and brain [14].
Allergic bronchopulmonary aspergillosis (ABPA) is a
hypersensitivity reaction to the Aspergillus fungus, similar
to AAS. However, this reaction occurs in the airways [3].
ABPA is almost exclusively seen in patients with cystic
ﬁbrosis or asthma [2]. The estimated prevalence of ABPA
among patients with asthma is approximately 1–2% [4].
The prevalence is slightly higher in patients with cystic
ﬁbrosis, estimating about 2–9% [5]. In rare cases, ABPA
can be seen in lung transplant recipients or those with
bronchiectasis, chronic granulomatous disease, or hyperIgE syndrome [6].
Diagnosis of ABPA is often made using the ISHAM
criteria (Table 1) [7]. This patient presented with both
“obligatory criteria” (elevated serum IgE concentration and
elevated IgE levels against Aspergillus fumigatus). He also
met two of the “other criteria” (tree-in-bud nodularity and
bronchiectasis and total eosinophil count > 500 cells/μL).
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This case is unique in that the patient did not have any of the
predisposing conditions. ISHAM notes that a diagnosis of
ABPA can still be made despite not presenting with these
conditions although this is rare.
ABPA is characterized by mucoid bronchial obstruction,
resulting in wheezing and rhonchi. Given the background of
hypersensitivity in this disease, patients typically have associated
eosinophilia and eosinophilic pneumonia [15]. Despite the severity of Aspergillus colonization, the fungi do not invade
bronchial walls. In most cases, the presence of fungal spores in
the lungs results in the formation of IgG and IgA against the
antigens. These are suﬃcient enough to clear the Aspergillus [16].
In patients with a history of atopy, additional IgE antibodies also
form, manifesting as the hypersensitivity reaction of ABPA.
Similar to the pathogenesis of asthma, CD4+ helper T cells
also play a role in the development of ABPA [17]. When exposed
to fungus, helper T cells secrete interleukins (IL), which include
IL-4, IL-5, and IL-13 [18]. In response to the interleukins, the
body produces IgE and eosinophils, contributing even more so
to the common ﬁnding of eosinophilia. Mucus plugs contain
Charcot–Leyden crystals and eosinophils. Culture of these plugs
may or may not grow the Aspergillus fungus [15].
Chronic airway hyperreactivity due to ABPA can result
in the development of bronchiectasis. Chest radiographs
often reveal thickened bronchial walls and atelectasis secondary to mucoid plugs [19]. Initial pulmonary function
testing presents with an obstructive pattern of changes,
including an increased residual volume (RV) and a decreased forced expiratory volume in one second (FEV1) [20].
Recommended treatment focuses on controlling inﬂammation and is usually a taper of systemic glucocorticoids
over three to six months.
ABPA is rarely reported in patients without asthma or
cystic ﬁbrosis. This patient is unique in that he did not meet
the ISHAM predisposing conditions usually required for
diagnosis of ABPA. It is important to note that this is a single
case of such association, which does not warrant enough
evidence to claim that chronic cocaine use and previously
treated tuberculosis increase risk for ABPA. Nevertheless, it
is our hope to make healthcare providers aware of its potential presence in chronic cocaine users and patients with
tuberculosis, both of which are not traditionally associated
with this condition.
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